These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

795 related items for PubMed ID: 20335831

  • 1. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M.
    Transplantation; 2010 Apr 27; 89(8):994-1000. PubMed ID: 20335831
    [Abstract] [Full Text] [Related]

  • 2. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM.
    Transplantation; 2010 Jul 15; 90(1):31-7. PubMed ID: 20517177
    [Abstract] [Full Text] [Related]

  • 3. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 4. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C.
    Transplantation; 2009 Nov 27; 88(10):1194-202. PubMed ID: 19935373
    [Abstract] [Full Text] [Related]

  • 5. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
    McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS.
    Liver Transpl; 2001 Aug 27; 7(8):701-8. PubMed ID: 11510015
    [Abstract] [Full Text] [Related]

  • 6. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 7. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, Holman J, First MR, OPTIMA Study Group.
    Transplantation; 2008 Jul 15; 86(1):88-95. PubMed ID: 18622283
    [Abstract] [Full Text] [Related]

  • 8. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan 15; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

  • 9. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
    van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L.
    Transplantation; 2003 Jun 27; 75(12):1934-9. PubMed ID: 12829890
    [Abstract] [Full Text] [Related]

  • 10. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.
    Bechstein WO, Paczek L, Wramner L, Squifflet JP, Zygmunt AJ, European Rapamune Tacrolimus Study Group.
    Transplant Proc; 2013 Jun 27; 45(6):2133-40. PubMed ID: 23953523
    [Abstract] [Full Text] [Related]

  • 11. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 27; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 12. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Tedesco-Silva H, Medina-Pestana JO.
    Fundam Clin Pharmacol; 2007 Apr 27; 21(2):191-7. PubMed ID: 17391292
    [Abstract] [Full Text] [Related]

  • 13. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 27; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 14. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S, Fujita T, Yoneyama T, Yoneyama T, Koie T, Hashimoto Y, Saitoh H, Funyu T, Narumi S, Ohyama C.
    Transplant Proc; 2012 Jan 27; 44(1):121-3. PubMed ID: 22310594
    [Abstract] [Full Text] [Related]

  • 15. Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure.
    Romagnoli J, Citterio F, Favi E, Salerno MP, Tondolo V, Spagnoletti G, Renna R, Castagneto M.
    Transplant Proc; 2007 Jan 27; 39(6):1823-6. PubMed ID: 17692622
    [Abstract] [Full Text] [Related]

  • 16. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
    Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, Fritsche L, Soulillou JP, Fauchald P, Dantal J, RADW 102 Renal Transplant Study Group.
    Nephrol Dial Transplant; 2004 Oct 27; 19(10):2606-14. PubMed ID: 15316094
    [Abstract] [Full Text] [Related]

  • 17. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor.
    Brandhorst G, Tenderich G, Zittermann A, Oezpeker C, Koerfer R, Oellerich M, Armstrong VW.
    Ther Drug Monit; 2008 Feb 27; 30(1):113-6. PubMed ID: 18223473
    [Abstract] [Full Text] [Related]

  • 18. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.
    Transplantation; 2012 Nov 27; 94(10):1013-9. PubMed ID: 23073468
    [Abstract] [Full Text] [Related]

  • 19. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 20. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR, Vanrenterghem Y.
    Clin Ther; 2004 Nov 15; 26(11):1834-44. PubMed ID: 15639695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.